Search

everythinglearnresearchcommunity

for

Search:↓

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

Androgen deprivation therapy might be better for preventing COVID-19 than treating it.

AGA affects many, progresses differently, and early treatment is crucial.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.

No increased skin cancer risk was found in alopecia patients treated with photobiomodulation.

CT scans can find serious prostate cancer even when PSA levels are low.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Early-onset male baldness may indicate a higher risk of prostate cancer.

Early baldness in men may indicate a higher risk of prostate cancer.

Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.

Prostate cancer risk is not linked to blood testosterone levels.

CEC levels may be a useful marker for predicting prostate cancer progression.

Six new risk spots for early hair loss were found, which also link to Parkinson's disease and lower fertility. Two genes, FOXA2 and HDAC4, could be new treatment targets. Hair loss might also be connected to heart disease, metabolic syndrome, and prostate cancer.

Gene variation affects prostate issues and hair loss.

Some breast cancer chemotherapy can cause permanent hair loss.

Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

PCOS may increase the risk of certain cancers.

Cancer rates are increasing in developed countries, with estrogen, aging, low vitamin D3, and HPV infection as common causes.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.

Certain spices may help prevent and treat skin cancer, but more human trials are needed.